High-mobility group box 1 mediates persistent splenocyte priming in sepsis survivors: Evidence from a murine model

Shock

Volumn 40, Issue 6, 2013, Pages 492-495

  Valdés Ferrer, Sergio I ^a,b   Rosas Ballina, Mauricio ^b,c   Olofsson, Peder S ^b   Lu, Ben ^a,b   Dancho, Meghan E ^b   Li, Jianhua ^b   Yang, Huan ^b   Pavlov, Valentin A ^b   Chavan, Sangeeta S ^b   Tracey, Kevin J ^b  

^a Elmezzi Graduate School of Molecular Medicine   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

HMGB1; priming; splenocyte dysregulation

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; EX VIVO STUDY; FLOW CYTOMETRY; IMMUNE RESPONSE; MALE; MORTALITY; MOUSE; MURINE MODEL; NONHUMAN; PATHOGENESIS; PERITONEAL CAVITY; SEPSIS; SPLEEN; SPLEEN CELL; SPLENOMEGALY; SURVIVOR;

ANIMALS; ANTIBODIES, NEUTRALIZING; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; HMGB1 PROTEIN; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, IMMUNOLOGIC; SEPSIS; SPLEEN; SPLENOMEGALY; TOLL-LIKE RECEPTOR 4;

EID: 84888137939     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000050     Document Type: Article

References (26)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7):1303-1310, 2001.
2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348(16): 1546-1554, 2003.
3. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B: Deaths: final data for 2007. Natl Vital Stat Rep 58(19):1-135, 2010.
4. Iwashyna TJ, Cooke CR, Wunsch H, Kahn JM: Population burden of long-term survivorship after severe sepsis in older Americans. J Am Geriatr Soc 60(6): 1070-1077, 2012.
5. Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G: Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med 31(9): 2316-2323, 2003.
6. Williams TA, Dobb GJ, Finn JC, Knuiman MW, Geelhoed E, Lee KY, Webb SA: Determinants of long-term survival after intensive care. Crit Care Med 36(5): 1523-1530, 2008.
7. Cuthbertson BH, Roughton S, Jenkinson D, Maclennan G, Vale L: Quality of life in the five years after intensive care: a cohort study. Crit Care 14(1):R6, 2010.
8. Valdés-Ferrer SI, Rosas-Ballina M, Olofsson PS, Lu B, Dancho ME, Ochani M, Li JH, Scheinerman JA, Katz DA, Levine YA, et al. : Treatment with anti-HMGB1 nmAb normalizes leukocyte counts, splenomegaly and splenocyte cytokine response to endotoxin in murine sepsis survivors [published online ahead of print]. J Intern Med 274(4):381-390, 2013.
9. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H: HMGB1 signals through Toll-like receptor (TLR) 4 and TLR2. Shock 26(2):174-179, 2006.
10. van Zoelen MAD, Yang H, Florquin S, Meijers JC, Akira S, Arnold B, Nawroth PP, Bierhaus A, Tracey KJ, van der Poll T: Role of Toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1Yinduced inflammation in vivo. Shock 31(3):280-284, 2009.
11. Andersson U, Tracey KJ: HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29:139-162, 2011.
12. Chavan SS, Huerta PT, Robbiati S, Valdes-Ferrer SI, Ochani M, Dancho M, Frankfurt M, Volpe BT, Tracey KJ, Diamond B: HMGB1 mediates cognitive impairment in sepsis survivors. Mol Med 18(1):930-937, 2012.
13. Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moldawer LL, Efron PA: Cecal Ligation and Puncture. Curr Protoc Immunol 91:19. 13. 1-19. 13. 11, 2010.
14. Angus DC, Yang L, Kong L, Kellum JA, Delude RL, Tracey KJ, Weissfeld L; GenIMS Investigators: Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 35(4):1061-1067, 2007.
15. Lantos J, Földi V, Roth E, Wéber G, Bogár L, Csontos C: Burn trauma induces early hmgb1 release in patients: its correlation with cytokines. Shock 33(6): 562-567, 2010.
16. Huang LF, Yao YM, Dong N, Yu Y, He LX, Sheng ZY: Association of high mobility group box-1 protein levels with sepsis and outcome of severely burned patients. Cytokine 53(1):29-34, 2011.
17. Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ: Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33(3):564-573, 2005.
18. Yasuda T, Ueda T, Takeyama Y, Shinzeki M, Sawa H, Nakajima T, Ajiki T, Fujino Y, Suzuki Y, Kuroda Y: Significant Increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 33(4):359-363, 2006.
19. Rosas-Ballina M Goldstein RS, Gallowitsch-Puerta M, Yang L, Valdés-Ferrer SI, Patel NB, Chavan S, Al-Abed Y, Yang H, Tracey KJ: The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol Med 15(7-8):195-202, 2009.
20. Pavlov VA, Ochani M, Yang LH, Gallowitsch-Puerta M, Ochani K, Lin X, Levi J, Parrish WR, Rosas-Ballina M, Czura CJ, et al. : Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med 35(4):1139-1144, 2007.
21. Rosas-Ballina M, Ochani M, Parrish WR, et al. : Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci U S A 105(31):11008-11013, 2008.
22. Remick DG: Pathophysiology of sepsis. Am J Pathol 170(5):1435-1444, 2007.
23. Cohen J: The immunopathogenesis of sepsis. Nature 420(6917):885-891, 2002.
24. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348(2):138-150, 2003.
25. Rigato O, Salomao R: Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis. Shock 19(2):113-116, 2003.
26. Matera G, Puccio R, Giancotti A, Quirino A, Pulicari MC, Zicca E, Caroleo S, Renzulli A, Liberto MC, Focà A: Impact of interleukin-10, soluble CD25 and interferon-+ on the prognosis and early diagnosis of bacteremic systemic inflammatory response syndrome: a prospective observational study. Crit Care 17(2):R64, 2013.